Peregrine Pharmaceuticals Submits Clinical Protocol to Initiate Bavituximab Phase II Trial in Patients With Metastatic Bre... ( TUSTIN Calif. Sept. 10 /- Peregri...)

HOME >> MEDICINE >> TECHNOLOGY

Peregrine Pharmaceuticals Submits Clinical Protocol to Initiate Bavituximab Phase II Trial in Patients With Metastatic Breast Cancer

Date:9/10/2007

TUSTIN, Calif., Sept. 10 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), a clinical stage biopharmaceutical company developing monoclonal antibodies for the treatment of cancer and hepatitis C virus (HCV) infection, today announced that it has submitted a clinical protocol with the Drug Controller General of India (DCGI) for an open label Phase II safety and efficacy trial of bavituximab in combination with the chemotherapy drugs paclitaxel and carboplatin in patients with metastatic breast cancer. The multi-center trial is expected to begin enrolling patients pending regulatory and ethics committee approvals.

The trial has a two-stage design. Up to 15 patients with metastatic breast cancer will be enrolled initially and the study will be expanded up to a total of 46 patients if promising results are observed in the first cohort. The primary objective is to assess the overall response rate to the combination of bavituximab with doses of paclitaxel and carboplatin. Secondary objectives include measuring time to tumor progression, duration of response, overall patient survival and safety parameters. Patients may continue to receive weekly administration of bavituximab with weekly doses of paclitaxel and carboplatin as long as their cancer does not progress, unless side effects require earlier cessation of therapy.

"The filing of this second cancer clinical protocol reflects our strategy of fielding a number of targeted Phase II combination studies in specific cancer indications," said Steven W. King, president and CEO of Peregrine. "Despite advances in treatment, breast cancer remains a major source of mortality among women. We designed this study using data generated from our recen
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4
Related medicine technology :

1. Peregrine Pharmaceuticals Reports Positive Top-Line Results in Bavituximab Combination Therapy Trial in Advanced Cancer Patients
2. Positive Results Using Affitech-Identified Human Antibody That Blocks VEGF Binding to VEGF Receptor 2 in Preclinical Cancer Model Reported by Peregrine
3. Peregrine Pharmaceuticals Highlights Significant Advances in the Companys Clinical and Preclinical Cancer Programs Presented This Week at the AACR Annual Meeting
4. Data Presented at AACR Meeting Shows Peregrines Immunocytokine Fusion Proteins Reduce Growth of B-Cell Lymphoma Tumors by 85% in Preclinical Studies
5. Data Presented at AACR Meeting Show Peregrines Bavituximab Equivalent Can Generate Curative Immune Responses as Part of a Vaccine-Like Regimen in Preclinical Models of Aggressive Brain Cancer
6. Data Presented at AACR Meeting Shows Peregrines Selective Anti-VEGF Antibodies are as Effective as Avastin(R) in Preclinical Cancer Models
7. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
8. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
9. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
10. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
11. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference

Post Your Comments:

(Date:8/18/2008)...O, Aug. 18 /- The next time you consi...ff, it might be worth counting sheep,instead. A se...er in San,Diego, Calif. has found evidence that ta...k of skin cancer., Daniel F. Kripke, M.D.,s artic...eeping pills and cancer, has just been published i...

(Date:8/18/2008)...iates Clinical Trials Phase of Test Development Pr...-FirstCall/ -- Beckman,Coulter, Inc. (NYSE: BEC )...y out its U.S. royalty obligation to Nephromics LL... women,s health. The license is for tests,related ...f preeclampsia, a,leading cause of maternal death....

(Date:8/17/2008)...Australia, Aug. 17 /Xinhua-...ed that the first pivotal Phase 3,clinical trial o...has,completed enrolment., The first efficacy data... the first half of 2009. The trial commenced its d...ruitment target of 250 subjects in June,2008 and c...

(Date:8/14/2008)...N, N.J., Aug. 14 /- Pharmas...aceutical company committed to,discovering, develo...l,infections, reported unaudited financial results... Pharmasset reported a net loss attributable to,co...share of $0.69 for the,quarter ended June 30, 2008...

[1] Prescription Sleeping Pill Use Tied to Cancer [0] Beckman Coulter Buys Out Royalty Obligation for Preeclampsia Markers [1] Bronchitol Phase 3 Cystic Fibrosis Trial Completes Recruitment [0] Pharmasset Reports Financial Results for Quarter Ended June 30, 2008

...NCISCO--(BUSINESS WIRE)--May 21, 2007 - Gilead Sci...of two long-term studies,evaluating ambrisentan, a...ERA) for the treatment of patients with pulmonary,...are from patients,who originally participated in t..., a Phase II study of patients who had,previously ...

... product recently approved by FDA for long-term,ma...ata demonstrate,first nebulized formoterol fumarat...y powder formoterol, enhanced patient quality of,l...y 20, 2007) – Data presented at the,Internat...(ATS),demonstrate that Perforomist™ (formote...

Other Medicine Technology:Gilead Announces Presentation of Long-Term Data for Ambrisentan, a,Potential Treatment for Patients With Pulmonary Arterial,Hypertension 2 Gilead Announces Presentation of Long-Term Data for Ambrisentan, a,Potential Treatment for Patients With Pulmonary Arterial,Hypertension 3 Gilead Announces Presentation of Long-Term Data for Ambrisentan, a,Potential Treatment for Patients With Pulmonary Arterial,Hypertension 4 Gilead Announces Presentation of Long-Term Data for Ambrisentan, a,Potential Treatment for Patients With Pulmonary Arterial,Hypertension 5 Gilead Announces Presentation of Long-Term Data for Ambrisentan, a,Potential Treatment for Patients With Pulmonary Arterial,Hypertension 6 Clinical Trial Data for Perforomist (Formoterol Fumarate),Inhalation Solution Presented at International ATS Conference 2 Clinical Trial Data for Perforomist (Formoterol Fumarate),Inhalation Solution Presented at International ATS Conference 3 Clinical Trial Data for Perforomist (Formoterol Fumarate),Inhalation Solution Presented at International ATS Conference 4 Clinical Trial Data for Perforomist (Formoterol Fumarate),Inhalation Solution Presented at International ATS Conference 5 Clinical Trial Data for Perforomist (Formoterol Fumarate),Inhalation Solution Presented at International ATS Conference 6 Clinical Trial Data for Perforomist (Formoterol Fumarate),Inhalation Solution Presented at International ATS Conference 7

Gilead Announces Presentation of Long-Term Data for Ambrisentan, a,Potential Treatment for Patients With Pulmonary Arterial,Hypertension Clinical Trial Data for Perforomist (Formoterol Fumarate),Inhalation Solution Presented at International ATS Conference

(Date:8/20/2008)...r-old Contestant Wins Trip to Little League Baseba... The National Spit Tobacco Education,Program (NSTE...st today,and encouraged young baseball players to...ddiction and the health risks of using tobacco pro...year,s slogan contest winner is,Joe Reck, a nine-y...

(Date:8/20/2008)...cently enacted Medicare Improvement Law immediatel...re Advantage insurance companies .../PRNewswire/ -- When the House and Senate,overrode...gislation,protecting Medicare beneficiaries, they ...e Advantage plans during one of the busiest months...

(Date:8/20/2008)...T CREEK, Calif., Aug. 20 /PRNewswire-FirstCall/ --... reported preliminary income from,continuing opera...f $27.5,million, or $0.76 per diluted share, inclu...er diluted share, related to provisions for store,... a 6.8 percent increase,compared with income from ...

(Date:8/20/2008)...FIELD, Mich., Aug. 20 /PRNewswire/ -- WXYZ- TV/Cha...llness Promotion will give thousands of,Detroit me...ALTHY LIVING,FOR KIDS" program. This year the prog....m. to 5 p.m. at the Charles H. Wright Museum of A...77, "Healthy Living for Kids",has provided free im...

[0] Slogan Contest Educates Young Baseball Players About the Dangers of Tobacco Use [0] Medicare Advantage Plans Struggle to Comply With New Federal Law [0] Longs Drug Stores Corporation Reports Second Quarter Results [0] WXYZ-TV/Channel 7 is 'On Your Side' With Healthy Living For Kids; Free Immunizations for Children on Sunday, August 24 at Charles H. Wright Museum of African American History

...nti-inflammatory drug Dicolofenec on the country's...as decided to withdraw licences for manufacturing ...ay, the director of the prominent NGO Bombay Natur...ani, presented a copy of Drug Controller General A...

...at the grapes in most red wines have a sleep induc...son why wine lulls //people to beauty sleep. Melat...and in the brain, which is like a sign board for t... The discovery of melatonin in grape skin could e...

... a curse many men suffer, is thankfully out of the...t ED, //many men are finding solutions to their pr...r sexual dysfunction, it is increasingly important...cialties to become proficient in the mechanisms an...

...the lives of wild and laboratory rodents seems to ...une systems when exposed //to germs in the environ...of researchers from Duke University analyzed the i...s which live in laboratories with those which live...

Other Medicine News:Health News:Host of Benefits from Erectile Dysfunction Drugs 2 Health News:Host of Benefits from Erectile Dysfunction Drugs 3

Drug Controller General to Withdraw Drug that Affects Vulture Population Grapes are not sour…Host of Benefits from Erectile Dysfunction Drugs A booster for immune systems: unhygienic environs?

.../Cuff combines the therapeutic benefits of control...ing, and cold to minimize pain. The cuff is anatom...ing maximum cryotherapy. The Elbow Cryo/Cuff is av...c size.,All Cryo/Cuffs can be ordered as a single ...

...; ROM Elbow Orthosis features aluminum cuffs that ...r joint alignment, unique slot/screw adjustment me...l adjustments to cuff position. Cuffs are configur...with contractures.,The hinge can be locked in any...

...CTION Elbow Wrap replaces messy taping and bulky e...s experiencing epicondylitis. Preferred by doctors...y fit. Two overlay straps allow you to apply force...lds the Elbow Wrap comfortably in place. Available...

The Bledsoe Original Arm Brace is designed to handle post-op elbow arthroscopy, severe elbow strains and ligament trauma. The Bledsoe Extender Arm Brace should be used when limited R.O.M. or locked c

Medicine Products:

Elbow Cryo/Cuff™QualCare™ ROM Elbow Orthosis ACTION™ Elbow Wrap Bledsoe Original Arm Brace

Peregrine Pharmaceuticals Submits Clinical Protocol to Initiate Bavituximab Phase II Trial in Patients With Metastatic Bre...( TUSTIN Calif. Sept. 10 /- Peregri...),Health